27546025|t|Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography / tandem mass spectrometry
27546025|a|A remediable cause of poor treatment response in drug - susceptible tuberculosis (TB) patients may be low plasma levels of one or more of the first-line anti-TB drugs. The aim of this work was to develop an accurate and precise LC-MS / MS method for simultaneous quantification of all four first-line anti-TB drugs in plasma suitable for therapeutic drug monitoring (TDM). To adjust for degradation and losses during sample preparation, isotopically labeled compounds were used as internal standards. Plasma samples spiked with internal standards were extracted using protein precipitation with methanol and acetonitrile. Simultaneous separation of all four drugs was accomplished with a Chromolith Reversed-Phase column and mobile phases consisting of water, methanol, ammonium acetate and formic acid with subsequent mass spectrometric quantification. The linear range of the calibration curve for isoniazid was 0.5-10 mg/L, for rifampicin 0.75-30 mg/L, for ethambutol 0.25-10 mg/L and for pyrazinamide 4-80 mg/L. The lower limit of quantification was 0.5 mg/L, 0.75 mg/L, 0.25 mg/L and 4.0 mg/L, respectively. Precision estimated by the coefficient of variation was <15% for all four drugs. The LC-MS / MS method can readily be used for simultaneous quantification of first-line anti-TB drugs in plasma and is well suited for TDM.
27546025	31	40	isoniazid	T103	UMLS:C0022209
27546025	42	52	rifampicin	T103	UMLS:C0035608
27546025	54	64	ethambutol	T103	UMLS:C0014964
27546025	69	81	pyrazinamide	T103	UMLS:C0034239
27546025	85	106	liquid chromatography	T058	UMLS:C0008565
27546025	136	146	remediable	T058	UMLS:C1709895
27546025	156	179	poor treatment response	T033	UMLS:C1320680
27546025	183	187	drug	T103	UMLS:C1254351
27546025	202	214	tuberculosis	T038	UMLS:C0041296
27546025	216	218	TB	T038	UMLS:C0041296
27546025	240	246	plasma	T031	UMLS:C0032105
27546025	287	300	anti-TB drugs	T103	UMLS:C0003237
27546025	362	367	LC-MS	T058	UMLS:C0872318
27546025	370	372	MS	T058	UMLS:C0037813
27546025	435	448	anti-TB drugs	T103	UMLS:C0003237
27546025	452	458	plasma	T031	UMLS:C0032105
27546025	472	499	therapeutic drug monitoring	T058	UMLS:C1720825
27546025	501	504	TDM	T058	UMLS:C1720825
27546025	571	601	isotopically labeled compounds	T103	UMLS:C0022262
27546025	635	649	Plasma samples	T031	UMLS:C0444263
27546025	686	695	extracted	T058	UMLS:C0022885
27546025	702	723	protein precipitation	T058	UMLS:C3815102
27546025	729	737	methanol	T103	UMLS:C0001963
27546025	742	754	acetonitrile	T103	UMLS:C0050456
27546025	792	797	drugs	T103	UMLS:C0013227
27546025	859	872	mobile phases	T103	UMLS:C3469601
27546025	887	892	water	T103	UMLS:C0043047
27546025	894	902	methanol	T103	UMLS:C0001963
27546025	904	920	ammonium acetate	T103	UMLS:C0051704
27546025	925	936	formic acid	T103	UMLS:C0016576
27546025	1034	1043	isoniazid	T103	UMLS:C0022209
27546025	1065	1075	rifampicin	T103	UMLS:C0035608
27546025	1094	1104	ethambutol	T103	UMLS:C0014964
27546025	1126	1138	pyrazinamide	T103	UMLS:C0034239
27546025	1321	1326	drugs	T103	UMLS:C0013227
27546025	1332	1337	LC-MS	T058	UMLS:C0872318
27546025	1340	1342	MS	T058	UMLS:C0037813
27546025	1416	1429	anti-TB drugs	T103	UMLS:C0003237
27546025	1433	1439	plasma	T031	UMLS:C0032105
27546025	1463	1466	TDM	T058	UMLS:C1720825